Pulmonary hypertension, frequently complicating the course of patients with fibrotic
interstitial lung disease, is associated with significantly increased morbidity and mortality …

Pulmonary hypertension is a debilitating condition that frequently develops in the setting of
interstitial lung disease, likely related to chronic alveolar hypoxemia and pulmonary vascular …

Abstract Background and Objective Pulmonary hypertension is a life‐limiting complication of
interstitial lung disease (ILD‐PH). We investigated whether treatment with …

Erratum: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:
Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the …

Right heart (RH) failure carries a high rate of morbidity and mortality. Patients who present
with RH failure often exhibit complex aberrant cardio-pulmonary physiology with varying …

The effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10
infants with chronic pulmonary arterial hypertension. Respiratory status (n= 8/10), right heart …

Abstract Background Since the latest 2017 French guidelines, knowledge about idiopathic
pulmonary fibrosis has evolved considerably. Methods Practical guidelines were drafted on …

Upfront combination therapy including intravenous prostaglandin I2 (PGI2-IV) is recognized
as the most appropriate treatment for patients with severe pulmonary arterial hypertension …

Connective tissue diseases (CTDs) can be associated with various forms of pulmonary
hypertension, including pulmonary arterial hypertension (PAH), pulmonary veno‐occlusive …

Pulmonary hypertension (PH) is a common complication of chronic lung diseases,
particularly in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases …